Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

Aaron D Goldberg, MDPhD, Mark B. Geyer, MD, Jonathan Kell, MD, Eros Di Bona, MD, Timothy S. Pardee, MDPhD, Rupali Bhave, MD, Michael R. Grunwald, MD, Giovanni Marconi, MD, Yijia Wang, MD MPH, Asif Pathan, PhD RPh, Boo Messahel, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-139898

Published: 2020

Journal Articles

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

John Mascarenhas, MD, Heidi E. Kosiorek, MS, Lilian Varricchio, PhD, Rupali Bhave, MD, Andrew T. Kuykendall, MD, Rami Komrokji, MD, Aaron T. Gerds, MDMS, Jeanne M. Palmer, MD, Amelia R. Gabler, Lonette Sandy, Anna Rita Migliaccio, PhD, Mohamed E Salama, MD, Rona Singer Weinberg, PhD, Maureen O'Connor-McCourt, PhD, Gilles Tremblay, PhD, Paul I. Nadler, MD, Amylou C. Dueck, PhD, Ruben A. Mesa, MD FACP, Ronald Hoffman, MD

Blood (2020) 136 (Supplement 1): 6–8.

https://doi.org/10.1182/blood-2020-140830

Published: 2020

Journal Articles

Frontline Selinexor and Chemotherapy Is Highly Active in Older Adults with Acute Myeloid Leukemia (AML)

Timothy S. Pardee, MDPhD, Kristin M. Pladna, M.S., Susan Lyerly, P.A.-C., Sarah Dralle, Megan Manuel, NP, Leslie Renee Ellis, MD MSHPEd, Dianna S. Howard, MD, Rupali Bhave, MD, Bayard L. Powell, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139999

Published: 2020

Journal Articles

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Laura A Bowers, PharmD, Maho Hibino, PharmD, Rebecca Garcia Hunt, PharmD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Dianna S. Howard, MD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Timothy S. Pardee, MD PhD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 3901.

https://doi.org/10.1182/blood-2019-131817

Published: 2019

Journal Articles

Assessing Efficacy and Safety of Daunorubicin and Cytarabine Liposomal in Patients with Acute Myeloid Leukemia

Elizabeth Rogers, PharmD, MPH, Maho Hibino, PharmD, Rebecca Garcia Hunt, PharmD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Dianna S. Howard, MD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Timothy S. Pardee, MD PhD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 5134.

https://doi.org/10.1182/blood-2019-131328

Published: 2019

Journal Articles

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Timothy S. Pardee, MD PhD, Kris C Wood, PhD, Kevin H Lin, BS, Justine Rutter, PhD, Mariaelena Pierobon, MD, Emanuel Petricoin, PhD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 1388.

https://doi.org/10.1182/blood-2019-129413

Published: 2019

Journal Articles

Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia

Anjali S. Advani, MD, Anna Moseley, M.S., Kristen Marie O'Dwyer, MD, Brent Wood, MDPhD, Min Fang, MDPhD, Matthew J. Wieduwilt, MD PhD, Ibrahim Aldoss, MD, Jae H. Park, MD, Rebecca Klisovic, MD, Maria R. Baer, MD, Wendy Stock, MD, Rupali Bhave, MD, Megan Othus, PhD, Mark R. Litzow, MD, Richard M. Stone, MD, Harry P. Erba, MDPhD

Blood (2018) 132 (Supplement 1): 33.

https://doi.org/10.1182/blood-2018-99-111992

Published: 2018

Journal Articles

Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and Refractory AML

Timothy Pardee, MDPhD, Scott Isom, M.S., Leslie Renee Ellis, MD MSHPEd, Dianna S. Howard, MD, Rupali Bhave, MD, Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD

Blood (2018) 132 (Supplement 1): 1355.

https://doi.org/10.1182/blood-2018-99-118991

Published: 2018

Journal Articles

Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)

Blood (2018) 132 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2018-99-111935

Published: 2018

Journal Articles

Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy

Meagan Scott, PharmD, Maho Hibino, PharmD, Marie Cavalier, PharmD, Bayard L. Powell, MD, Dianna S. Howard, MD, Leslie Renee Ellis, MD, Rupali Bhave, MD, Susan Lyerly, P.A.-C., Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Timothy S Pardee, MD PhD

Blood (2017) 130 (Supplement 1): 2091.

https://doi.org/10.1182/blood.V130.Suppl_1.2091.2091

Published: 2017

Journal Articles

Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

Timothy S Pardee, MD PhD, Scott Isom, M.S., Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD

Blood (2017) 130 (Supplement 1): 2626.

https://doi.org/10.1182/blood.V130.Suppl_1.2626.2626

Published: 2017

Journal Articles

Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated with a Modified CALGB 10102 Regimen in a Real World Setting

Margaux Wooster, B.S., Scott Isom, M.S., Leslie Renee Ellis, MD, Dianna S. Howard, MD, Megan Manuel, M.S.N, Rupali Bhave, MD, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD, Timothy S Pardee, MD PhD

Blood (2017) 130 (Supplement 1): 5044.

https://doi.org/10.1182/blood.V130.Suppl_1.5044.5044

Published: 2017

NARROW

Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib

Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with Myelofibrosis: MPN-RC 118 Trial

Frontline Selinexor and Chemotherapy Is Highly Active in Older Adults with Acute Myeloid Leukemia (AML)

Evaluating the Utilization of All- T rans Retinoic Acid and Arsenic Trioxide during Consolidation Therapy for Patients Receiving Treatment for Acute Promyelocytic Leukemia

Assessing Efficacy and Safety of Daunorubicin and Cytarabine Liposomal in Patients with Acute Myeloid Leukemia

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia

Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and Refractory AML

Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)

Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy

Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated with a Modified CALGB 10102 Regimen in a Real World Setting

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only